866-997-4948(US-Canada Toll Free)

Relapsed Multiple Myeloma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 169 Pages



Global Markets Directs, \'Relapsed Multiple Myeloma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Relapsed Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma. Relapsed Multiple Myeloma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Relapsed Multiple Myeloma.
  • A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Relapsed Multiple Myeloma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Relapsed Multiple Myeloma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Relapsed Multiple Myeloma 10
Relapsed Multiple Myeloma Therapeutics under Development by Companies 12
Relapsed Multiple Myeloma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Relapsed Multiple Myeloma Therapeutics - Products under Development by Companies 18
Relapsed Multiple Myeloma Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Relapsed Multiple Myeloma Therapeutics Development 21
Bristol-Myers Squibb Company 21
Johnson & Johnson 22
Kyowa Hakko Kirin Co., Ltd. 23
Genentech, Inc. 24
Piramal Healthcare Limited 25
Prolexys Pharmaceuticals, Inc. 26
Millennium Pharmaceuticals, Inc. 27
Novartis AG 28
Astellas Pharma Inc. 29
ImmunoGen, Inc. 30
Exelixis, Inc. 31
Onyx Pharmaceuticals, Inc. 32
Incyte Corporation 33
AEterna Zentaris Inc. 34
Pharmacyclics, Inc. 35
Array BioPharma Inc. 36
MorphoSys AG 37
Senesco Technologies, Inc. 38
Synta Pharmaceuticals Corp. 39
Acceleron Pharma, Inc. 40
Altor BioScience Corporation 41
Stemline Therapeutics, Inc. 42
Acetylon Pharmaceuticals, Inc. 43
PharmaMar, S.A. 44
Cylene Pharmaceuticals, Inc. 45
Centocor Ortho Biotech, Inc. 46
Relapsed Multiple Myeloma - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
perifosine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
bendamustine hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lorvotuzumab mertansine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ibrutinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BMS-833923 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
panobinostat - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
dalantercept - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dasatinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ganetespib - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ruxolitinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ARRY-520 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
ALT-801 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
BMS-936564 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
veliparib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
plitidepsin - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
silmitasertib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
quisinostat - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
MV-NIS Vaccine - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
ABT-199 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
RG-7598 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
LGH-447 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
hydroxychloroquine + sirolimus + [cyclophosphamide] + [dexamethasone acetate] - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
chloroquine + [bortezomib] + [cyclophosphamide] - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Melflufen - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Circularly Permuted TRAIL - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Relapsed Multiple Myeloma Therapeutics - Drug Profile Updates 109
Relapsed Multiple Myeloma Therapeutics - Discontinued Products 156
Relapsed Multiple Myeloma Therapeutics - Dormant Products 157
Relapsed Multiple Myeloma - Product Development Milestones 158
Featured News & Press Releases 158
Aug 20, 2013: Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients 158
Aug 09, 2013: Celgene\'s Pomalidomide oral anti-cancer therapy wins European Commission approval 158
Jun 17, 2013: Acetylon Pharma Presents Encouraging Safety And Clinical Response Data From Ongoing Clinical Trials Of ACY-1215 For Treatment Of Multiple Myeloma 159
Jun 03, 2013: Takeda Pharmaceutical Reports Results From Phase I Study Of MLN9708 At ASCO 2013 Annual Meeting 160
Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 161
May 31, 2013: Celgene\'s Oral Anti-Cancer Therapy Pomalidomide Receives Positive CHMP Opinion As Treatment for Patients With Relapsed And Refractory Multiple Myeloma 163
May 21, 2013: Onyx Pharma Announces Presentation Of Data Highlighting Kyprolis At 18th EHA Annual Meeting 2013 164
May 20, 2013: Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference 165
May 15, 2013: Onyx Pharma To Present Data On Kyprolis At 49th American Society Of Clinical Oncology Annual Meeting 165
Apr 22, 2013: Senesco Completes Cohort 2 Of Its Phase Ib/IIa Trial Of SNS01-T 166

Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
Expert Panel Validation 168
Contact Us 169
Disclaimer 169

List of Table


Number of Products Under Development for Relapsed Multiple Myeloma, H2 2013 10
Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Development by Companies, H2 2013 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2013 20
Bristol-Myers Squibb Company, H2 2013 21
Johnson & Johnson, H2 2013 22
Kyowa Hakko Kirin Co., Ltd., H2 2013 23
Genentech, Inc., H2 2013 24
Piramal Healthcare Limited, H2 2013 25
Prolexys Pharmaceuticals, Inc., H2 2013 26
Millennium Pharmaceuticals, Inc., H2 2013 27
Novartis AG, H2 2013 28
Astellas Pharma Inc., H2 2013 29
ImmunoGen, Inc., H2 2013 30
Exelixis, Inc., H2 2013 31
Onyx Pharmaceuticals, Inc., H2 2013 32
Incyte Corporation, H2 2013 33
AEterna Zentaris Inc., H2 2013 34
Pharmacyclics, Inc., H2 2013 35
Array BioPharma Inc., H2 2013 36
MorphoSys AG, H2 2013 37
Senesco Technologies, Inc., H2 2013 38
Synta Pharmaceuticals Corp., H2 2013 39
Acceleron Pharma, Inc., H2 2013 40
Altor BioScience Corporation, H2 2013 41
Stemline Therapeutics, Inc., H2 2013 42
Acetylon Pharmaceuticals, Inc., H2 2013 43
PharmaMar, S.A., H2 2013 44
Cylene Pharmaceuticals, Inc., H2 2013 45
Centocor Ortho Biotech, Inc., H2 2013 46
Assessment by Monotherapy Products, H2 2013 47
Assessment by Combination Products, H2 2013 48
Assessment by Stage and Route of Administration, H2 2013 50
Assessment by Stage and Molecule Type, H2 2013 52
Relapsed Multiple Myeloma Therapeutics - Drug Profile Updates 109
Relapsed Multiple Myeloma Therapeutics - Discontinued Products 156
Relapsed Multiple Myeloma Therapeutics - Dormant Products 157

List of Chart


Number of Products under Development for Relapsed Multiple Myeloma, H2 2013 10
Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 47
Assessment by Combination Products, H2 2013 48
Assessment by Route of Administration, H2 2013 49
Assessment by Stage and Route of Administration, H2 2013 50
Assessment by Molecule Type, H2 2013 51
Assessment by Stage and Molecule Type, H2 2013 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *